IN BRIEF: Avacta widens annual loss on research, manufacturing costs
6th Apr 2022 10:23
Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to GBP29.2 million from GBP18.9 million in 2020. However, revenue rises to GBP2.9 million from GBP2.1 million. Like the year before, there will be no dividends. Read More